ADC Name	MTX-13
Synonyms	MTX-13; DAY301; CB-002    Click to Show/Hide
Organization	Multitude Therapeutics (Originator);Maxis Biotech (Originator);Day One Biopharma
Drug Status	Phase 1
Drug-to-Antibody Ratio	8
Structure
				2D MOL
Antibody Name	Ab13					Antibody Info
Antigen Name	Inactive tyrosine-protein kinase 7 (PTK7)					Antigen Info
Payload Name	Exatecan					Payload Info
Payload Target	DNA topoisomerase 1 (TOP1)					Target Info
Linker Name	T1000					Linker Info
Conjugate Type	Random Cysteines
Combination Type	sesutecan

Standard Type	Value	Units	Description	Reference
Time to Maximum Concentration (Tmax)	0±0	day	The pharmacokinetic parameters of MTX-13, 15 mg/kg, first dose.	[1]
Time to Maximum Concentration (Tmax)	0±0	day	The pharmacokinetic parameters of MTX-13, 30 mg/kg, first dose.	[1]
Time to Maximum Concentration (Tmax)	0±0	day	The pharmacokinetic parameters of MTX-13, 15 mg/kg, second dose.	[1]
Time to Maximum Concentration (Tmax)	0.04±0.06	day	The pharmacokinetic parameters of MTX-13, 30 mg/kg, second dose.	[1]
Time to Maximum Concentration (Tmax)	0±0	day	The pharmacokinetic parameters of MTX-13, 15 mg/kg, third dose.	[1]
Time to Maximum Concentration (Tmax)	0±0	day	The pharmacokinetic parameters of MTX-13, 30 mg/kg, third dose.	[1]
Maximum Observed Concentration (Cmax)	447.5±12.02	ug/mL	The pharmacokinetic parameters of MTX-13, 15 mg/kg, first dose.	[1]
Maximum Observed Concentration (Cmax)	1008.5±44.55	ug/mL	The pharmacokinetic parameters of MTX-13, 30 mg/kg, first dose.	[1]
Maximum Observed Concentration (Cmax)	419.5±23.33	ug/mL	The pharmacokinetic parameters of MTX-13, 15 mg/kg, second dose.	[1]
Maximum Observed Concentration (Cmax)	897.5±27.58	ug/mL	The pharmacokinetic parameters of MTX-13, 30 mg/kg, second dose.	[1]
Maximum Observed Concentration (Cmax)	537±24.04	ug/mL	The pharmacokinetic parameters of MTX-13, 15 mg/kg, third dose.	[1]
Maximum Observed Concentration (Cmax)	1295±21.21	ug/mL	The pharmacokinetic parameters of MTX-13, 30 mg/kg, third dose.	[1]
Area Under the Concentration-Time Curve (AUC)	2672.02±776.73	day·ug/mL	The pharmacokinetic parameters of MTX-13, 15 mg/kg, first dose, AUCinf.	[1]
Area Under the Concentration-Time Curve (AUC)	5893.05±866.64	day·ug/mL	The pharmacokinetic parameters of MTX-13, 30 mg/kg, first dose, AUCinf.	[1]
Area Under the Concentration-Time Curve (AUC)	2689.63±343.69	day·ug/mL	The pharmacokinetic parameters of MTX-13, 15 mg/kg, second dose, AUCinf.	[1]
Area Under the Concentration-Time Curve (AUC)	6254.58±40.59	day·ug/mL	The pharmacokinetic parameters of MTX-13, 30 mg/kg, second dose, AUCinf.	[1]
Area Under the Concentration-Time Curve (AUC)	3318.53±374.81	day·ug/mL	The pharmacokinetic parameters of MTX-13, 15 mg/kg, third dose, AUCinf.	[1]
Area Under the Concentration-Time Curve (AUC)	7782.81±455.72	day·ug/mL	The pharmacokinetic parameters of MTX-13, 30 mg/kg, third dose, AUCinf.	[1]

Standard Type	Value	Units	Description	Reference
Volume of Distribution (Vd)	50.01±8.9	mL/kg	The pharmacokinetic parameters of MTX-13, 15 mg/kg, first dose.	[1]
Volume of Distribution (Vd)	49.64±5.32	mL/kg	The pharmacokinetic parameters of MTX-13, 30 mg/kg, first dose.	[1]
Volume of Distribution (Vd)	51.38±9.06	mL/kg	The pharmacokinetic parameters of MTX-13, 15 mg/kg, second dose.	[1]
Volume of Distribution (Vd)	46.24±5.5	mL/kg	The pharmacokinetic parameters of MTX-13, 30 mg/kg, second dose.	[1]
Volume of Distribution (Vd)	35.91±5.74	mL/kg	The pharmacokinetic parameters of MTX-13, 15 mg/kg, third dose.	[1]
Volume of Distribution (Vd)	32.56±0.22	mL/kg	The pharmacokinetic parameters of MTX-13, 30 mg/kg, third dose.	[1]

Standard Type	Value	Units	Description	Reference
Elimination Half-Life (t1/2)	7.99±1.57	day	MTX-13's in vivo pharmacokinetics was evaluated in H1975 tumor-bearing mice model. There was no clear difference in plasma concentration of MTX-13 and total Ab (Fig. 2G), MTX-13 is stable with a similar half-life (T1/2 7.99 ± 1.57 days) as naked Ab13 (T1/2 7.46 ± 1.04 days; Supplementary Fig. S4H).    Click to Show/Hide	[1]
Elimination Half-Life (t1/2)	6.66±0.5	day	The pharmacokinetic parameters of MTX-13, 15 mg/kg, first dose.	[1]
Elimination Half-Life (t1/2)	7.48±0.01	day	The pharmacokinetic parameters of MTX-13, 30 mg/kg, first dose.	[1]
Elimination Half-Life (t1/2)	6.71±0.58	day	The pharmacokinetic parameters of MTX-13, 15 mg/kg, second dose.	[1]
Elimination Half-Life (t1/2)	7.02±0.98	day	The pharmacokinetic parameters of MTX-13, 30 mg/kg, second dose.	[1]
Elimination Half-Life (t1/2)	5.46±0.53	day	The pharmacokinetic parameters of MTX-13, 15 mg/kg, third dose.	[1]
Elimination Half-Life (t1/2)	6.01±0.27	day	The pharmacokinetic parameters of MTX-13, 30 mg/kg, third dose.	[1]
Clearance (CL)	5.86±1.7	mL/day/kg	The pharmacokinetic parameters of MTX-13, 15 mg/kg, first dose.	[1]
Clearance (CL)	5.15±0.76	mL/day/kg	The pharmacokinetic parameters of MTX-13, 30 mg/kg, first dose.	[1]
Clearance (CL)	5.62±0.72	mL/day/kg	The pharmacokinetic parameters of MTX-13, 15 mg/kg, second dose.	[1]
Clearance (CL)	4.8±0.03	mL/day/kg	The pharmacokinetic parameters of MTX-13, 30 mg/kg, second dose.	[1]
Clearance (CL)	4.55±0.51	mL/day/kg	The pharmacokinetic parameters of MTX-13, 15 mg/kg, third dose.	[1]
Clearance (CL)	3.86±0.23	mL/day/kg	The pharmacokinetic parameters of MTX-13, 30 mg/kg, third dose.	[1]

Ref 1	MTX-13, a Novel PTK7-Directed Antibody-Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors